Viewing nowPregabalin 150 mg Capsule
Pregabalin 150mg
Hard capsule · Prescription medication
SaeHan Pharmaceutical Co., Ltd.

MFDS item code 201109159 · Approved 2011.10.25 · Insurance code 651300480
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of epilepsy (partial-onset seizures)
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also effective as an adjunctive treatment for partial seizures in epilepsy, whether accompanied by secondary generalized symptoms or not. Additionally, it is used in the treatment of fibromyalgia, helping to alleviate patient symptoms. This drug is useful in various neurological disorders and contributes to improving the quality of life of patients.
This medication is administered orally, regardless of food, in 2 divided doses of the total daily dose of pregabalin. Because this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Because the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (ml/min)* *: For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: A supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Administration is not recommended for children under 12 years of age and adolescent patients aged 12 to 17 years because sufficient safety and efficacy data are not available.
This medication may increase the risk of suicidal thoughts or behaviors and mental health issues such as depression during use, so patients and caregivers should inform healthcare professionals immediately if such symptoms occur. This medication should not be used in patients with hypersensitivity to its components, and diabetic patients may require adjustment of their blood glucose control medications due to weight gain. Allergic reactions such as angioedema may occur, so if symptoms such as swelling of the face or around the mouth appear, discontinue use immediately. Elderly patients may experience more severe dizziness or drowsiness, so caution is needed until they are accustomed to these symptoms when taking this medication. Vision may become blurred or change; if these symptoms occur, consult a healthcare professional. Abruptly discontinuing this medication may cause withdrawal symptoms such as insomnia, headache, and anxiety, so dosage adjustments should be made according to the healthcare provider's instructions. There is a risk of drug abuse, so patients with a history of drug abuse or mental disorders should take caution, and monitoring for unusual behavior is necessary. Patients with impaired kidney function may need dose adjustments for this medication. Patients with heart disease should exercise caution when taking this medication, especially those with congestive heart failure. Co-administration with opioid analgesics may increase the risk of central nervous system depression, so caution is needed. Patients with weak respiratory function or the elderly are at risk for severe respiratory depression, so dose adjustments and close monitoring are necessary. During early pregnancy, there is a risk of fetal malformation, so it is recommended that pregnant women do not take this medication, and women of childbearing age should use effective birth control methods. Breastfeeding women should consider stopping breastfeeding or discontinuing this medication as it may be passed into breast milk. It is safest to avoid dangerous activities such as driving or operating machinery until dizziness or drowsiness has resolved after taking this medication. Severe allergic reactions may occur on the skin, so if rash or skin abnormalities occur, discontinue use immediately and consult a healthcare professional. In case of overdose, symptoms may include mental confusion, drowsiness, depression, requiring immediate treatment. Keep this medication out of reach of children and do not transfer to other containers as maintaining quality is important.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, maintaining a storage temperature between 15 and 30 degrees Celsius. Proper storage will help sustain the medication's effectiveness for a longer period.
Hard capsules with a white upper and a white lower part containing white or gray-white crystalline powder.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
SaeHan Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.